By integrating insights from transmembrane adaptor proteins, like TMEPAI, transcriptional regulators such as SALL4, oncoprotein coactivators similar to TCL1B, and cytokine signals akin to TGF‐β, we gain a more holistic understanding of how PI3K/AKT is hyperactivated in cancer. This evidence concerns the gene PMEPA1 and cancer.